サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：臓器移植拒絶反応薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2022年から2031年
市場調査レポート
商品コード
1301470

臓器移植拒絶反応薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2022年から2031年

Organ Transplant Rejection Medication Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 241 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
臓器移植拒絶反応薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2022年から2031年
出版日: 2023年05月10日
発行: Transparency Market Research
ページ情報: 英文 241 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

臓器移植拒絶反応薬市場- レポートの範囲

世界の臓器移植拒絶反応薬市場に関するTMRのレポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。 このレポートは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界の臓器移植拒絶反応薬市場の収益を提供しています。また、2023年から2031年までの世界の臓器移植拒絶反応薬市場の年間平均成長率（CAGR %）も掲載しています。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、臓器移植拒絶反応薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界の臓器移植拒絶反応薬市場の競合情勢を詳しく掘り下げています。世界の臓器移植拒絶反応薬市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の臓器移植拒絶反応薬市場のプレーヤーの属性です。

目次

第1章 序文

第2章 仮定と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • 現在の世界のシナリオ：移植のための臓器提供
  • 主要製品/ブランド分析
  • パイプライン分析
  • COVID-19の影響分析

第6章 世界市場の分析と予測：医薬品クラス別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：医薬品クラス別、2017-2031
    • 抗体
      • チモグロブリン
      • アレムツズマブ
      • ベラタセプト
      • ムロモナブ-CD3
      • バシリキシマブ
      • エクリズマブ
    • 代謝拮抗物質
      • アザチオプリン
      • ミコフェノール酸モフェチル
      • ミコフェノール酸ナトリウム、MPA
    • カルシニューリン阻害剤
      • シクロスポリン
      • タクロリムス
    • mTOR阻害剤
      • シロリムス
      • エベロリムス
    • ステロイド
      • プレドニゾロン
      • メチルプレドニゾロン
  • 市場魅力分析：医薬品クラス別

第7章 世界市場の分析と予測：移植タイプ別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：移植タイプ別、2017-2031
    • 腎臓
    • 肝臓
    • 心臓
    • 肺
    • 膵臓
    • その他
  • 市場魅力分析：移植タイプ別

第8章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：流通チャネル別、2017-2031
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力分析：流通チャネル別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東およびアフリカ市場の分析と予測

第15章 競合情勢

  • 市場企業- 競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Pfizer, Inc.
    • Astellas Pharma, Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc
    • AbbVie, Inc.
    • Hansa Biopharma
    • WOCKHARDT
    • Viatris, Inc.
    • Glenmark
    • Biocon
    • Hikma Pharmaceuticals plc
    • Teva Pharmaceutical USA Inc.
    • Zydus Pharmaceuticals, Inc.
図表

List of Tables

  • Table 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 03: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 04: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 05: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 06: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 10: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 12: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 13: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 14: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 15: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 16: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 17: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 19: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 20: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 21: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 22: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 23: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 24: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 25: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 26: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 27: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 28: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 29: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 30: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 31: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 32: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 33: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 34: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 35: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 36: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 37: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 38: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 39: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 40: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 41: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 42: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 43: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 44: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 45: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 46: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 47: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 48: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 49: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 50: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 51: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 52: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 53: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 54: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Organ Transplant Rejection Medications Market Value Share, by Drug Class, 2022
  • Figure 03: Global Organ Transplant Rejection Medications Market Value Share, by Transplant Type, 2022
  • Figure 04: Global Organ Transplant Rejection Medications Market Value Share, by Distribution Channel, 2022
  • Figure 05: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 06: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antibodies, 2017-2031
  • Figure 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antimetabolites, 2017-2031
  • Figure 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Calcineurin Inhibitors, 2017-2031
  • Figure 10: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by mTOR Inhibitors, 2017-2031
  • Figure 11: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Steroids, 2017-2031
  • Figure 12: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 13: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 14: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Kidney, 2017-2031
  • Figure 15: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Liver, 2017-2031
  • Figure 16: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Heart, 2017-2031
  • Figure 17: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Lung, 2017-2031
  • Figure 18: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Pancreas, 2017-2031
  • Figure 19: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 20: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 21: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 22: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 23: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 24: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 25: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 26: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 27: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 29: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 30: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 31: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 32: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 34: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 35: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 36: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 38: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 39: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 40: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 41: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 43: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 44: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 45: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 47: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 48: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 49: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 50: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 51: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 52: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 53: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 54: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 55: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 56: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 57: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 58: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 59: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 60: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 61: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 62: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 63: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 64: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 65: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 66: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 67: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 68: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 69: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 70: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 71: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
目次
Product Code: TMRGL76123

Organ Transplant Rejection Medication Market - Scope of Report

TMR's report on the global Organ Transplant Rejection Medication market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Organ Transplant Rejection Medication market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Organ Transplant Rejection Medication market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Organ Transplant Rejection Medication market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Organ Transplant Rejection Medication market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Organ Transplant Rejection Medication market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Organ Transplant Rejection Medication market.

The report delves into the competitive landscape of the global Organ Transplant Rejection Medication market. Key players operating in the global Organ Transplant Rejection Medication market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Organ Transplant Rejection Medication market profiled in this report.

Key Questions Answered in Global Organ Transplant Rejection Medication Market Report:

  • What is the sales/revenue generated by Organ Transplant Rejection Medication across all regions during the forecast period?
  • What are the opportunities in the global Organ Transplant Rejection Medication market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Organ Transplant Rejection Medication Market - Research Objectives and Research Approach

The comprehensive report on the global Organ Transplant Rejection Medication market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Organ Transplant Rejection Medication market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Organ Transplant Rejection Medication market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Organ Transplant Rejection Medication Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Organ Transplant Rejection Medication Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Current Global Scenario: Organ Donation for Transplantation
  • 5.2. Key Product/Brand Analysis
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Impact Analysis

6. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Antibodies
      • 6.3.1.1. Thymoglobulin
      • 6.3.1.2. Alemtuzumab
      • 6.3.1.3. Belatacept
      • 6.3.1.4. Muromonab-CD3
      • 6.3.1.5. Basiliximab
      • 6.3.1.6. Eculizumab
    • 6.3.2. Antimetabolites
      • 6.3.2.1. Azathioprine
      • 6.3.2.2. Mycophenolate Mofetil
      • 6.3.2.3. Mycophenolate sodium, MPA
    • 6.3.3. Calcineurin Inhibitors
      • 6.3.3.1. Cyclosporine
      • 6.3.3.2. Tacrolimus
    • 6.3.4. mTOR Inhibitors
      • 6.3.4.1. Sirolimus
      • 6.3.4.2. Everolimus
    • 6.3.5. Steroids
      • 6.3.5.1. Prednisolone
      • 6.3.5.2. Methylprednisolone
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Transplant Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 7.3.1. Kidney
    • 7.3.2. Liver
    • 7.3.3. Heart
    • 7.3.4. Lung
    • 7.3.5. Pancreas
    • 7.3.6. Others
  • 7.4. Market Attractiveness Analysis, by Transplant Type

8. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Organ Transplant Rejection Medication Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. Antibodies
      • 10.2.1.1. Thymoglobulin
      • 10.2.1.2. Alemtuzumab
      • 10.2.1.3. Belatacept
      • 10.2.1.4. Muromonab-CD3
      • 10.2.1.5. Basiliximab
      • 10.2.1.6. Eculizumab
    • 10.2.2. Antimetabolites
      • 10.2.2.1. Azathioprine
      • 10.2.2.2. Mycophenolate Mofetil
      • 10.2.2.3. Mycophenolate sodium, MPA
    • 10.2.3. Calcineurin Inhibitors
      • 10.2.3.1. Cyclosporine
      • 10.2.3.2. Tacrolimus
    • 10.2.4. mTOR Inhibitors
      • 10.2.4.1. Sirolimus
      • 10.2.4.2. Everolimus
    • 10.2.5. Steroids
      • 10.2.5.1. Prednisolone
      • 10.2.5.2. Methylprednisolone
  • 10.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 10.3.1. Kidney
    • 10.3.2. Liver
    • 10.3.3. Heart
    • 10.3.4. Lung
    • 10.3.5. Pancreas
    • 10.3.6. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Transplant Type
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Organ Transplant Rejection Medication Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Antibodies
      • 11.2.1.1. Thymoglobulin
      • 11.2.1.2. Alemtuzumab
      • 11.2.1.3. Belatacept
      • 11.2.1.4. Muromonab-CD3
      • 11.2.1.5. Basiliximab
      • 11.2.1.6. Eculizumab
    • 11.2.2. Antimetabolites
      • 11.2.2.1. Azathioprine
      • 11.2.2.2. Mycophenolate Mofetil
      • 11.2.2.3. Mycophenolate sodium, MPA
    • 11.2.3. Calcineurin Inhibitors
      • 11.2.3.1. Cyclosporine
      • 11.2.3.2. Tacrolimus
    • 11.2.4. mTOR Inhibitors
      • 11.2.4.1. Sirolimus
      • 11.2.4.2. Everolimus
    • 11.2.5. Steroids
      • 11.2.5.1. Prednisolone
      • 11.2.5.2. Methylprednisolone
  • 11.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 11.3.1. Kidney
    • 11.3.2. Liver
    • 11.3.3. Heart
    • 11.3.4. Lung
    • 11.3.5. Pancreas
    • 11.3.6. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Transplant Type
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Organ Transplant Rejection Medication Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Antibodies
      • 12.2.1.1. Thymoglobulin
      • 12.2.1.2. Alemtuzumab
      • 12.2.1.3. Belatacept
      • 12.2.1.4. Muromonab-CD3
      • 12.2.1.5. Basiliximab
      • 12.2.1.6. Eculizumab
    • 12.2.2. Antimetabolites
      • 12.2.2.1. Azathioprine
      • 12.2.2.2. Mycophenolate Mofetil
      • 12.2.2.3. Mycophenolate sodium, MPA
    • 12.2.3. Calcineurin Inhibitors
      • 12.2.3.1. Cyclosporine
      • 12.2.3.2. Tacrolimus
    • 12.2.4. mTOR Inhibitors
      • 12.2.4.1. Sirolimus
      • 12.2.4.2. Everolimus
    • 12.2.5. Steroids
      • 12.2.5.1. Prednisolone
      • 12.2.5.2. Methylprednisolone
  • 12.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 12.3.1. Kidney
    • 12.3.2. Liver
    • 12.3.3. Heart
    • 12.3.4. Lung
    • 12.3.5. Pancreas
    • 12.3.6. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Transplant Type
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Organ Transplant Rejection Medication Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Antibodies
      • 13.2.1.1. Thymoglobulin
      • 13.2.1.2. Alemtuzumab
      • 13.2.1.3. Belatacept
      • 13.2.1.4. Muromonab-CD3
      • 13.2.1.5. Basiliximab
      • 13.2.1.6. Eculizumab
    • 13.2.2. Antimetabolites
      • 13.2.2.1. Azathioprine
      • 13.2.2.2. Mycophenolate Mofetil
      • 13.2.2.3. Mycophenolate sodium, MPA
    • 13.2.3. Calcineurin Inhibitors
      • 13.2.3.1. Cyclosporine
      • 13.2.3.2. Tacrolimus
    • 13.2.4. mTOR Inhibitors
      • 13.2.4.1. Sirolimus
      • 13.2.4.2. Everolimus
    • 13.2.5. Steroids
      • 13.2.5.1. Prednisolone
      • 13.2.5.2. Methylprednisolone
  • 13.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 13.3.1. Kidney
    • 13.3.2. Liver
    • 13.3.3. Heart
    • 13.3.4. Lung
    • 13.3.5. Pancreas
    • 13.3.6. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Transplant Type
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Organ Transplant Rejection Medication Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Antibodies
      • 14.2.1.1. Thymoglobulin
      • 14.2.1.2. Alemtuzumab
      • 14.2.1.3. Belatacept
      • 14.2.1.4. Muromonab-CD3
      • 14.2.1.5. Basiliximab
      • 14.2.1.6. Eculizumab
    • 14.2.2. Antimetabolites
      • 14.2.2.1. Azathioprine
      • 14.2.2.2. Mycophenolate Mofetil
      • 14.2.2.3. Mycophenolate sodium, MPA
    • 14.2.3. Calcineurin Inhibitors
      • 14.2.3.1. Cyclosporine
      • 14.2.3.2. Tacrolimus
    • 14.2.4. mTOR Inhibitors
      • 14.2.4.1. Sirolimus
      • 14.2.4.2. Everolimus
    • 14.2.5. Steroids
      • 14.2.5.1. Prednisolone
      • 14.2.5.2. Methylprednisolone
  • 14.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 14.3.1. Kidney
    • 14.3.2. Liver
    • 14.3.3. Heart
    • 14.3.4. Lung
    • 14.3.5. Pancreas
    • 14.3.6. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Transplant Type
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer, Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Astellas Pharma, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Novartis AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. F. Hoffmann-La Roche Ltd.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Sanofi
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. GlaxoSmithKline plc
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. AbbVie, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Hansa Biopharma
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. WOCKHARDT
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Business Strategies
      • 15.3.10.4. Recent Developments
    • 15.3.11. Viatris, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments
    • 15.3.12. Glenmark
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Product Portfolio
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Developments
    • 15.3.13. Biocon
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Financial Overview
      • 15.3.13.3. Product Portfolio
      • 15.3.13.4. Business Strategies
      • 15.3.13.5. Recent Developments
    • 15.3.14. Hikma Pharmaceuticals plc
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Financial Overview
      • 15.3.14.3. Product Portfolio
      • 15.3.14.4. Business Strategies
      • 15.3.14.5. Recent Developments
    • 15.3.15. Teva Pharmaceutical U.S.A Inc.
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Financial Overview
      • 15.3.15.3. Product Portfolio
      • 15.3.15.4. Business Strategies
      • 15.3.15.5. Recent Developments
    • 15.3.16. Zydus Pharmaceuticals, Inc.
      • 15.3.16.1. Company Overview
      • 15.3.16.2. Financial Overview
      • 15.3.16.3. Product Portfolio
      • 15.3.16.4. Business Strategies
      • 15.3.16.5. Recent Developments